Stockreport

IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

AstraZeneca PLC - American Depositary Shares  (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE) [Read more]